ENCLAI Daily · Article of the day 02 Oct 2026 · ENCLAI Editorial

Survodutide reduces weight by 9.8% in adults with obesity and type 2 diabetes

NEW MEDICAL STUDY · RANDOMISED TRIAL · 02 OCTOBER 2026Survodutide reduces weight by 9.8% inadults with obesity and type 2 diabetesPubMed 42820639Randomised trialStudy typeNEJMjournal1 Oct 2026publishedIn a phase 3 trial, adults with obesity and type 2 diabetes whoreceived once-weekly survodutide lost significantly more weightthan those on placebo. The 6.0-mg dose produced a mean weightreduction of 9.8% at week 76, compared with 3.9% for placebo.What the study found1At week 76, the mean weight change was -8.2% (95% CI, -9.2 to -7.2) inthe 3.6-mg group and -9.8% (95% CI, -10.8 to -8.8) in the 6.0-mggroup, compared with -3.9% (95% CI, -4.9 to -2.9) in the placebogroup.2Weight reduction of at least 5% from baseline occurred in 57.6% of the3.6-mg group, 64.5% of the 6.0-mg group, and 35.1% of the placebogroup, with P<0.001 for all comparisons with placebo.Who it applies toThe trial included adults with type 2diabetes and a body-mass index of 27or higher. Participants were randomlyassigned in a 1:1:1 ratio to receiveonce-weekly subcutaneous survodutide(3.6 mg or 6.0 mg) or placebo.What it does not establishThe most common adverse events weregastrointestinal, occurring in 72.8%of the 3.6-mg group, 77.7% of the6.0-mg group, and 38.6% of the placebogroup; these were generally mild tomoderate and transient.The authors' conclusion“In adults with obesity and type 2 diabetes, survodutide at a weeklydose of 3.6 mg or 6.0 mg resulted in significantly greater weightreduction than placebo.”Summary of the published abstract, not medical advice. Read the paper before acting on it.Source: PubMed 42820639 · enclai.net/newsVerify every figure against the source before use; ENCLAI does not guarantee accuracy orcompleteness.
  1. In a phase 3 trial, adults with obesity and type 2 diabetes who received once-weekly survodutide lost significantly more weight than those on placebo.
  2. The 6.0-mg dose produced a mean weight reduction of 9.8% at week 76, compared with 3.9% for placebo.
  3. At week 76, the mean weight change was -8.2% (95% CI, -9.2 to -7.2) in the 3.6-mg group and -9.8% (95% CI, -10.8 to -8.8) in the 6.0-mg group, compared with -3.9% (95% CI, -4.9 to -2.9) in the placebo group.
  4. Weight reduction of at least 5% from baseline occurred in 57.6% of the 3.6-mg group, 64.5% of the 6.0-mg group, and 35.1% of the placebo group, with P<0.001 for all comparisons with placebo.
Customise it in Visual Studio
Infographic — study at a glance
What the authors report
Evidence and source
Infographic — study at a glance

The publication

In a phase 3 trial, adults with obesity and type 2 diabetes who received once-weekly survodutide lost significantly more weight than those on placebo. The 6.0-mg dose produced a mean weight reduction of 9.8% at week 76, compared with 3.9% for placebo.

Who the findings apply to

The trial included adults with type 2 diabetes and a body-mass index of 27 or higher.

Participants were randomly assigned in a 1:1:1 ratio to receive once-weekly subcutaneous survodutide (3.6 mg or 6.0 mg) or placebo.

The study population had a mean age of 55.7 years and a mean baseline BMI of 36.5, with 49.3% of participants being men.

Why this matters

For people managing both type 2 diabetes and obesity, weight loss is a central therapeutic goal. Survodutide, a dual glucagon and GLP-1 receptor agonist, demonstrated substantial weight reduction and glycated hemoglobin improvements, suggesting it may offer metabolic benefits beyond standard weight management.

What the study found

At week 76, the mean weight change was -8.2% (95% CI, -9.2 to -7.2) in the 3.6-mg group and -9.8% (95% CI, -10.8 to -8.8) in the 6.0-mg group, compared with -3.9% (95% CI, -4.9 to -2.9) in the placebo group.

Weight reduction of at least 5% from baseline occurred in 57.6% of the 3.6-mg group, 64.5% of the 6.0-mg group, and 35.1% of the placebo group, with P<0.001 for all comparisons with placebo.

The mean change in glycated hemoglobin level from a baseline of 7.4% was -0.9 percentage points in the 3.6-mg group, -0.8 percentage points in the 6.0-mg group, and -0.2 percentage points in the placebo group.

What the result does not establish

The most common adverse events were gastrointestinal, occurring in 72.8% of the 3.6-mg group, 77.7% of the 6.0-mg group, and 38.6% of the placebo group; these were generally mild to moderate and transient.

The trial was funded by Boehringer Ingelheim, and the results are based on the treatment-regimen estimand, which assessed effects regardless of whether the trial regimen was discontinued or interrupted or whether other antiobesity therapies were used.

Authors’ conclusion

“In adults with obesity and type 2 diabetes, survodutide at a weekly dose of 3.6 mg or 6.0 mg resulted in significantly greater weight reduction than placebo.”

Trial registration

Registered with the trial registry as NCT06066528. ENCLAI does not hold this registry record, so its details are not shown; follow the link to read it.

Registered with the trial registry as NCT06066528. ENCLAI does not hold this registry record, so its details are not shown; follow the link to read it.

Study and sources

Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes

Randomised trial · Phase 3 · NEJM · 2026-10-01

Sources and limitations

Share this briefing
ENCLAI tracks outbreaks like this live, from official sources worldwide. Start 7-day free trial  ·  Request a demo →

Follow ENCLAI News

Get new briefings in your news reader. No ENCLAI account needed.

The daily disease brief

One email a day: what changed in official disease reporting worldwide, with the source named for every number. Reported facts only — no forecasts and no interpretation.

Double opt-in — we send a confirmation link and nothing else until you click it. One-click unsubscribe on every email. See our privacy notice.